Biocon FDA-483
FDA has released the FDA-483 issued following a 2/7-2/15 inspection at Biocon Limited, a Bangalore, India, drug product manufacturer. The two inspection observations were:
- procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, adequately validated, and/or followed; and
- written records of investigations into unexplained discrepancies do not always include an adequate conclusion and follow-up.